We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
Read MoreHide Full Article
ResMed Inc. (RMD - Free Report) unveiled its first top-of-head connected nasal pillows mask — AirFit P30i — in the United States. This is the company’s second top-of-head connected Continuous Positive Airway Pressure (CPAP) mask designed to treat sleep apnea.
The rollout of the product is in sync with the company’s strategy of consistently strengthening its portfolio of sleep apnea devices.
More About the AirFit P30i
The AirFit P30i is equipped with a ‘tube-up’ connection, which helps to keep tubing out of the users’ way. The device enables the user to move and sleep in any position. With just two frame sizes and three cushions, the AirFit P30i conveniently fits 90% of wearers. This reflects on the product's flexibility.
Through a clinical study, it has been proved that the new nasal pillow mask is superior to contemporary models available in the market. Notably, twice the number of CPAP users reported that the AirFit P30i is easier and more comfortable to use.
AirFit P30i is already available in overseas markets like Europe, Australia and New Zealand. It will be commercially released throughout the United States and Canada on April 15 as well as other countries later this year.
Market Prospects
Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with more treatment options are anticipated to continue driving demand for sleep apnea devices. Per a Markets and Markets report, the global sleep apnea devices market is expected to witness a CAGR of 7.8% and reach $6.49 billion between 2018 and 2023.
Per the same report, North America is projected to be the largest market for sleep apnea devices in 2018. Considering abundant growth potential and the company’s position as the forerunner in the space, the product launch is likely to generate profits for ResMed.
Recent Developments
Of late, ResMed has been investing in several developments to maintain its lead position in the sleep disordered breathing (SDB) market.
In March 2019, the company launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and enhance patient satisfaction.
In January, ResMed launched the AirFit N30i — the first top-of-head-connected nasal CPAP mask — designed to treat sleep apnea in the United States.
Price Performance
In the past year, ResMed has underperformed the industry it belongs to. The stock has increased 2% compared with the industry’s rise of 11.3%.
Varian’s long-term earnings growth rate is projected at 8%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Amedisys’s long-term earnings growth rate is projected at 19.7%.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” -- and early investors stand to earn the biggest profits.
Image: Bigstock
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
ResMed Inc. (RMD - Free Report) unveiled its first top-of-head connected nasal pillows mask — AirFit P30i — in the United States. This is the company’s second top-of-head connected Continuous Positive Airway Pressure (CPAP) mask designed to treat sleep apnea.
The rollout of the product is in sync with the company’s strategy of consistently strengthening its portfolio of sleep apnea devices.
More About the AirFit P30i
The AirFit P30i is equipped with a ‘tube-up’ connection, which helps to keep tubing out of the users’ way. The device enables the user to move and sleep in any position. With just two frame sizes and three cushions, the AirFit P30i conveniently fits 90% of wearers. This reflects on the product's flexibility.
Through a clinical study, it has been proved that the new nasal pillow mask is superior to contemporary models available in the market. Notably, twice the number of CPAP users reported that the AirFit P30i is easier and more comfortable to use.
AirFit P30i is already available in overseas markets like Europe, Australia and New Zealand. It will be commercially released throughout the United States and Canada on April 15 as well as other countries later this year.
Market Prospects
Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with more treatment options are anticipated to continue driving demand for sleep apnea devices. Per a Markets and Markets report, the global sleep apnea devices market is expected to witness a CAGR of 7.8% and reach $6.49 billion between 2018 and 2023.
Per the same report, North America is projected to be the largest market for sleep apnea devices in 2018. Considering abundant growth potential and the company’s position as the forerunner in the space, the product launch is likely to generate profits for ResMed.
Recent Developments
Of late, ResMed has been investing in several developments to maintain its lead position in the sleep disordered breathing (SDB) market.
In March 2019, the company launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and enhance patient satisfaction.
In January, ResMed launched the AirFit N30i — the first top-of-head-connected nasal CPAP mask — designed to treat sleep apnea in the United States.
Price Performance
In the past year, ResMed has underperformed the industry it belongs to. The stock has increased 2% compared with the industry’s rise of 11.3%.
Zacks Ranks and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Varian Medical Systems , Penumbra, Inc (PEN - Free Report) , and Amedisys, Inc (AMED - Free Report) . Notably, each of these stocks currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Varian’s long-term earnings growth rate is projected at 8%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Amedisys’s long-term earnings growth rate is projected at 19.7%.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” -- and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>